Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

  • Donal Brennan
  • Sara Ek
  • Emma Doyle
  • Thomas Drew
  • Michael Foley
  • Grainne Flannelly
  • Darren P O´Conner
  • William M Gallagher
  • Sami Kilpinen
  • Olli-Pekka Kallioniemi
  • Karin Jirström
  • Colm O'Herlihy
  • Carl Borrebaeck
Publiceringsår: 2009
Språk: Engelska
Sidor: 1510-1517
Publikation/Tidskrift/Serie: European Journal of Cancer
Volym: 45
Nummer: 8
Dokumenttyp: Artikel i tidskrift
Förlag: IFAC & Elsevier Ltd.




Current prognostic molecular markers for epithelial ovarian cancer (EOC) are

insufficient. The aim of the current study was to investigate the role of Sox11 in EOC


Using an in silico transcriptomic screen Sox11 was identified as a potential EOC

biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)

in 76 EOC cases, which were analyzed using automated algorithms to develop a

quantitative scoring model.


Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.

Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in

40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).

Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS

after controlling for stage and grade.


These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is

associated with a decreased RFS and a more aggressive phenotype.


  • Immunology in the medical area


  • CREATE Health
  • ISSN: 1879-0852

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen